Female Health (Nasdaq: FHCO ) is expected to report Q1 earnings on Jan. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Female Health's revenues will grow 14.3% and EPS will grow 22.2%.
The average estimate for revenue is $9.9 million. On the bottom line, the average EPS estimate is $0.11.
Last quarter, Female Health booked revenue of $9.9 million. GAAP reported sales were 39% higher than the prior-year quarter's $7.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.29. GAAP EPS of $0.28 for Q4 were 75% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 58.0%, 150 basis points worse than the prior-year quarter. Operating margin was 32.1%, 40 basis points worse than the prior-year quarter. Net margin was 82.6%, 1,910 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $37.4 million. The average EPS estimate is $0.52.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 304 members out of 313 rating the stock outperform, and nine members rating it underperform. Among 63 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 63 give Female Health a green thumbs-up, and give it a red thumbs-down.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Female Health. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Female Health to My Watchlist.